{"type":"trials","record":{"id":41382,"source_id":"clinicaltrials-gov","external_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","brief_summary":"The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \\[nAMD\\], diabetic macular edema \\[DME\\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.","overall_status":"Active Not Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Hoffmann-La Roche","enrollment":6000,"countries":["United States","Argentina","Australia","Bulgaria","Canada","Chile","Croatia","Czechia","Denmark","Egypt","France","Germany","Hong Kong","Israel","Italy","Japan","Poland","Puerto Rico","Saudi Arabia","Singapore","Slovenia","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Arab Emirates","United Kingdom"],"start_date":"2022-11-21","completion_date":"2027-11-30","last_update_date":"2026-09-02","source_url":"https://clinicaltrials.gov/study/NCT05476926","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"VOYAGER","age_range":"18 Years","comparator":null,"organization":"Hoffmann-La Roche","interventions":["Faricimab","Port Delivery System with Ranibizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Visual Acuity from Baseline at 1 Year, per Approved Retinal Indication and Product — Baseline and 1 year","Change in Visual Acuity from Baseline Over Time, per Approved Retinal Indication and Product — Baseline, 3, 6, and 12 m…","Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time, per Approved Ret…","Number of Treatments Over Time, per Approved Retinal Indication and Product — At 3, 6, and 12 months, and annually ther…","Cumulative Time Spent on Each Treatment per Eye, Overall and per Treatment Regimen (Fixed, Treat-and-Extend, As Needed,…","Percentage of Eyes with Treatment Switch by Reason for Switch Over Time, per Approved Retinal Indication and Product —…","Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Ov…","Total Number of Visits per Year, per Approved Retinal Indication and Product — Annually (up to 5 years)","Number of Visits With or Without Treatment per Year, per Approved Retinal Indication and Product — Annually (up to 5 ye…","Time Interval Between Treatments per Year, per Approved Retinal Indication and Product — Annually (up to 5 years)","Number of Eyes Treated with Ocular Concomitant and Subsequent Medications by Type and Frequency During the Study, per A…","Change in Visual Acuity from Baseline Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or…","Change in Visual Acuity from Baseline Over Time, According to Number of Treatments, per Approved Retinal Indication and…","Change in Visual Acuity from Baseline Over Time, According to Total Number of Visits, per Approved Retinal Indication a…","Change in Visual Acuity from Baseline Over Time, According to Treatment Schedule, per Approved Retinal Indication and P…","Change in Central Subfield Thickness (CST) from Baseline Over Time, per Approved Retinal Indication and Product — Basel…","Number of Participants with at Least One Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indica…","Number of Participants with at Least One Non-Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal In…"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Diabetic Macular Edema","Retinal Vein Occlusion","Branch Retinal Vein Occlusion","Central Retinal Vein Occlusion","Hemi-retinal Vein Occlusion","Faricimab","Port Delivery System with Ranibizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05476926","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-11-21 to 2027-11-30","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.802Z","intervention":["Faricimab","Port Delivery System with Ranibizumab"],"participants":6000,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Visual Acuity from Baseline at 1 Year, per Approved Retinal Indication and Product — Baseline and 1 year","Change in Visual Acuity from Baseline Over Time, per Approved Retinal Indication and Product — Baseline, 3, 6, and 12 m…","Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time, per Approved Ret…","Number of Treatments Over Time, per Approved Retinal Indication and Product — At 3, 6, and 12 months, and annually ther…","Cumulative Time Spent on Each Treatment per Eye, Overall and per Treatment Regimen (Fixed, Treat-and-Extend, As Needed,…","Percentage of Eyes with Treatment Switch by Reason for Switch Over Time, per Approved Retinal Indication and Product —…","Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Ov…","Total Number of Visits per Year, per Approved Retinal Indication and Product — Annually (up to 5 years)","Number of Visits With or Without Treatment per Year, per Approved Retinal Indication and Product — Annually (up to 5 ye…","Time Interval Between Treatments per Year, per Approved Retinal Indication and Product — Annually (up to 5 years)","Number of Eyes Treated with Ocular Concomitant and Subsequent Medications by Type and Frequency During the Study, per A…","Change in Visual Acuity from Baseline Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or…","Change in Visual Acuity from Baseline Over Time, According to Number of Treatments, per Approved Retinal Indication and…","Change in Visual Acuity from Baseline Over Time, According to Total Number of Visits, per Approved Retinal Indication a…","Change in Visual Acuity from Baseline Over Time, According to Treatment Schedule, per Approved Retinal Indication and P…","Change in Central Subfield Thickness (CST) from Baseline Over Time, per Approved Retinal Indication and Product — Basel…","Number of Participants with at Least One Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indica…","Number of Participants with at Least One Non-Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal In…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41382","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}